Abnormal fat buildup inside the brain’s immune cells may help to drive neurological damage and disability progression in people with progressive forms of multiple sclerosis (MS), a study found. The findings also point to a possible therapeutic target. Researchers showed that blocking an enzyme called MAGL may help reverse…

Three years of treatment with Sanofi’s investigational antibody therapy frexalimab was associated with persistently low disease activity and no new safety concerns in people with relapsing forms of multiple sclerosis (MS). That’s according to new data from an ongoing open-label extension phase of a global Phase…

It’s taken me three months to have enough distance and perspective to tell you about my once-in-a-lifetime trip that didn’t happen. I was all set to visit a favorite relative in Rome, with plans to stay in the dormitory of a 17th-century church with nuns. It was my first trip…

Subjective, patient-reported data on lived experiences should always be considered in the care of chronic conditions like multiple sclerosis (MS), according to a recent presentation. In a survey, many people with MS reported feeling that their lived experiences aren’t given enough consideration during visits with their care providers, and…